Your email has been successfully added to our mailing list.

×
0 -0.00181159420289851 0.00724637681159421 -0.0126811594202899 0.00724637681159421 0.00724637681159421 0.00724637681159421 0.00724637681159421
Stock impact report

ImmunoGen sells Kadcyla royalties for $65M [Seeking Alpha]

ImmunoGen, Inc. (IMGN) 
Last immunogen, inc. earnings: 5/1 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.immunogen.com/investor-relations
Company Research Source: Seeking Alpha
ImmunoGen sells Kadcyla royalties for $65MImmunoGen (NASDAQ:IMGN) hassold its Kadcyla (ado-trastuzumab) royalty stream to a Canadian pension plan called OMERS for $65M. The royalties were connected to certain patents licensed to Roche's Genentech unit which markets the breast cancer med. The FDA approved it in February 2013.Click to subscribe to real-time analytics on IMGNNow read:Sage Therapeutics Continues To Push Forward With Multiple Positive CNS Studies »Subscribefor full text news in your inbox Show less Read more
Impact Snapshot
Event Time:
IMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IMGN alerts
Opt-in for
IMGN alerts

from News Quantified
Opt-in for
IMGN alerts

from News Quantified